Reviewing Petros Pharmaceuticals (NASDAQ:PTPI) & Evotec (OTCMKTS:EVTCY)

Valuation & Earnings

This table compares Petros Pharmaceuticals and Evotec”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11 million	0.04	-$8.16 million	($39.69)	0.00
Evotec	$572.16 million	1.81	$7.14 million	$0.41	7.66

Evotec has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.3% of Petros Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Petros Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Evotec has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Petros Pharmaceuticals and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Evotec	20.85%	16.02%	7.81%

Summary

Evotec beats Petros Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Evotec

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.